Gut Liver.
2021 Jul;15(4):528-536. 10.5009/gnl20225.
Types of 23S Ribosomal RNA Point Mutations and Therapeutic Outcomes for Helicobacter pylori
- Affiliations
-
- 1Division of Gastroenterology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea
- 2Catholic Photomedicine Research Institute, College of Medicine, The Catholic University of Korea
- 3Division of Gastroenterology, Department of Internal Medicine, Eunpyeong St. Mary’s Hospital, College of Medicine, The Catholic University of Korea
- 4Clinical Trial Center, Ewha Womans University Mokdong Hospital, Seoul, Korea
- KMID: 2518446
- DOI: http://doi.org/10.5009/gnl20225
Abstract
- Background/Aims
Point mutations in the 23S ribosomal RNA gene have been associated with Helicobacter pylori clarithromycin resistance. This study aimed to detect the prevalence of these point mutations and to investigate the role of different point mutations in the success of eradication therapy.
Methods
We retrospectively investigated a total of 464 consecutive patients who underwent an endoscopic examination and dual-priming oligonucleotide-based multiplex polymerase chain reaction for H. pylori between June 2014 and October 2019. For 289 patients with negative point mutations, standard triple therapy was used in 287 patients, and the bismuth-quadruple regimen was used in two patients. For 175 patients with positive point mutations (A2142G, A2143G, and both mutations), standard triple and bismuth-quadruple therapies were used in 37 patients and 138 patients, respectively.
Results
The eradication rates of standard triple and bismuth-quadruple therapies showed no significant difference in mutation-negative patients or those with the A2142G point mutation. However, the eradication rate with bismuth-quadruple therapy was significantly higher than that with standard triple therapy in the group with the A2143G mutation or with the double mutation. The eradication rates for standard triple and bismuth-quadruple therapies, respectively, were 25.8% and 92.1% in the per-protocol group (p<0.001) and 24.2% and 85.2% in the intention-totreat analysis (p<0.001).
Conclusions
The A2143G point mutation is the most prevalent cause of clarithromycin resistance. Bismuth-quadruple therapy is superior to standard triple therapy in patients with the A2143G or double point mutation.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Eradication Therapy for Helicobacter pylori with Diagnostic Test for Clarithromycin Resistance
- Does Types of 23S-Ribosomal RNA Point Mutations Affect Helicobacter pylori Eradication Rate in Clarithromycin-Based Triple Therapy?
- Clarithromycin-resistant Helicobacter pylori Associated with 23S rRNA Point Mutations in Jeju Island
- Types of 23S Ribosomal RNA Point Mutations Affecting Helicobacter pylori Eradication Rates in Clarithromycin-Based Triple Therapy
- The Effect of Concomittent Therarpy and Quadruple Therapy for Patients Who Had 23S Ribosomal Ribonucleic Acid Mutated Helicobacter pylori in Daegu and Kyoungpook Area
